New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipeline
arcticnovartis
- NATALEE subanalysis evaluates Kisqali in pre-menopausal early breast cancer patients, amid rising diagnosis rates in younger patients
- Pluvicto analysis and Scemblix ASC4START primary endpoint results provide insights into use in earlier settings
- Fabhalta APPULSE-PNH full results build on Phase III program, reporting new data from expanded PNH population in adults switching from anti-C5
